Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer: How Response Impacts Locoregional and Adjuvant Systemic Therapy Decision Making
{{output}}
Neoadjuvant chemotherapy is now considered standard of care for most of the patients with clinically node-positive disease, and for a large proportion of triple-negative breast cancer and HER2-positive tumors. Here we reviewed the benefit of neoadjuvant chemot... ...
